Tag: mrna and next-generation vaccine platforms market growth

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Growth Potential: How Will Market Size Change Through 2030?

The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market size has experienced rapid expansion in recent years. This market is anticipated to increase from $39.69 billion in 2025 to $45.88 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 15.6%. The historical growth of this market can be attributed to covid 19 vaccine breakthroughs, prior viral vector research, global pandemic preparedness programs, advances in genomic sequencing, and early nucleic acid vaccine trials.

The messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market is projected to experience significant expansion in the coming years. It is forecast to reach $82.61 billion by 2030, driven by a compound annual growth rate (CAGR) of 15.8%. This growth during the forecast period can be attributed to several factors, including the increasing development of personalized cancer vaccines, the broadening of infectious disease pipelines, more rapid platform-based approvals, a surge in biotech funding, and the wider adoption of therapeutic vaccines. Furthermore, prominent trends anticipated during this period encompass self-amplifying mRNA platforms, optimized lipid nanoparticle delivery, modular vaccine platform design, swift adaptation to pathogen targets, and the emergence of next-generation adjuvant systems.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33215&type=smp&utm_source=Blogs&utm_medium=Paid&utm_campaign=Jul_PR

Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Growth Momentum: Which Factors Are Influencing Demand?

The rising need for individualized healthcare approaches is anticipated to drive expansion within the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market in the future. This medical strategy, personalized medicine, involves customizing disease prevention and treatment plans according to a person’s unique genetic makeup, molecular traits, and particular health status. The heightened requirement for personalized medicine stems from the increasing occurrence of intricate and long-term illnesses, given that such conditions necessitate precise, patient-focused therapeutic interventions to enhance the effectiveness and safety of treatments. Messenger ribonucleic acid (mRNA) and next-generation vaccine platforms facilitate personalized medicine by allowing for the quick, adaptable, and very specific creation of vaccines and therapies, which can be adapted to an individual’s genetic and disease characteristics, thereby promoting precise healthcare provision. An example illustrates this: in February 2024, the Personalized Medicine Coalition, a US-based hospital and health care organization, reported that the FDA approved 16 novel personalized treatments for patients with rare diseases in 2023, a notable increase from six in 2022. Consequently, the escalating need for personalized medicine is fostering the expansion of the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market.

Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Segment Analysis: What Are The Major Market Categories?

The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market covered in this report is segmented –

1) By Vaccine Type: Messenger Ribonucleic Acid Vaccines; Deoxyribonucleic Acid (DNA) Vaccines; Viral Vector Vaccines; Protein Subunit Vaccines; Peptide Vaccines; Other Vaccine Types

2) By Technology or Platform: Lipid Nanoparticle (LNP) Delivery; Self-Amplifying Messenger Ribonucleic Acid; Circular Messenger Ribonucleic Acid; Replicon or Non-replicating Platforms; Viral Vector Technologies

3) By Disease Indication: Infectious Diseases; Oncology; Rare Diseases; Other Disease Indications

4) By End User: Pharmaceutical and Biotechnology Companies; Contract Research Organizations (CROs); Academic and Research Institutes; Hospitals and Clinics

Subsegments:

1) By Messenger Ribonucleic Acid Vaccines: Conventional Messenger Ribonucleic Acid Vaccines; Self Amplifying Messenger Ribonucleic Acid Vaccines; Modified Messenger Ribonucleic Acid Vaccines; Circular Messenger Ribonucleic Acid Vaccines

2) By Deoxyribonucleic Acid Vaccines: Plasmid Deoxyribonucleic Acid Vaccines; Viral Assisted Deoxyribonucleic Acid Vaccines; Synthetic Deoxyribonucleic Acid Vaccines; Gene Based Deoxyribonucleic Acid Vaccines

3) By Viral Vector Vaccines: Adenovirus Based Viral Vector Vaccines; Lentivirus Based Viral Vector Vaccines; Poxvirus Based Viral Vector Vaccines; Measles Virus Based Viral Vector Vaccines

4) By Protein Subunit Vaccines: Recombinant Protein Vaccines; Virus Like Particle Vaccines; Toxoid Based Protein Vaccines; Polysaccharide Conjugate Vaccines

5) By Peptide Vaccines: Synthetic Peptide Vaccines; Personalized Peptide Vaccines; Multi Epitope Peptide Vaccines; Long Peptide Vaccines

6) By Other Vaccine Types: Protein Subunit Vaccines, Virus-Like Particle Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vector Vaccines

Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Trends Reshaping Industry Growth

Leading companies in the mRNA and next-generation vaccine platforms market are concentrating on the development of advanced mRNA-based COVID-19 vaccines to strengthen immune response duration, broaden coverage against variants, and elevate overall vaccine efficacy. These next-generation mRNA-based COVID-19 vaccines employ refined mRNA engineering and delivery techniques to offer more extensive and sustained protection against both existing and emerging SARS-CoV-2 variants. They also aim to improve safety, stability, and storage convenience, while facilitating rapid adaptation to viral evolution. For example, in June 2025, Moderna Inc., a US-based biotechnology company, launched mNEXSPIKE, its next-generation COVID-19 vaccine specifically crafted to enhance protection against circulating and emerging SARS-CoV-2 variants. This vaccine integrates an updated spike protein antigen that more closely corresponds to recent variants, seeking to provide improved immune durability and effectiveness, thereby supporting ongoing COVID-19 prevention strategies and future booster programs.

Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Leading Companies Driving Competitive Growth

Major companies operating in the messenger ribonucleic acid (mrna) and next-generation vaccine platforms market are Pfizer Inc., Sanofi S.A., AstraZeneca PLC, Thermo Fisher Scientific Inc., GSK plc, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Moderna Inc., BioNTech SE, Novavax Inc., Walvax Biotechnology Co Ltd, Arcturus Therapeutics Inc, Gennova Biopharmaceuticals Ltd, Vaxxas Pty Ltd, Vaxart Inc, Ethris GmbH, The Biologicals and Vaccines Institute of Southern Africa Proprietary Limited, eTheRNA Immunotherapies NV, Stemirna Therapeutics Co Ltd, Primrose Bio Inc, Acuitas Therapeutics Inc, and Incepta Vaccine Ltd.

Access The Complete Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Report:

https://www.thebusinessresearchcompany.com/report/messenger-ribonucleic-acid-mrna-and-next-generation-vaccine-platforms-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Jul_PR

#Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Largest Region: Which Geography Holds The Highest Market Share?

North America was the largest region in the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the messenger ribonucleic acid (mrna) and next-generation vaccine platforms market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Size Is Forecasted For The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market By 2030 Based On Its 2026 Value?

The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market has witnessed swift growth recently. It is projected to increase from $39.69 billion in 2025 to $45.88 billion in 2026, at a compound annual growth rate (CAGR) of 15.6%. The expansion observed in the past can be attributed to breakthroughs in COVID-19 vaccines, preceding viral vector research, global pandemic readiness programs, developments in genomic sequencing, and early trials of nucleic acid vaccines.

The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market is anticipated to undergo rapid expansion in the coming years. It is projected to reach $82.61 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 15.8%. This anticipated growth can be attributed to factors such as the rise of personalized cancer vaccines, the expansion of infectious disease pipelines, quicker platform-based approvals, increased funding in biotechnology, and broader use of therapeutic vaccines. Key trends during the forecast period are expected to include self-amplifying mRNA platforms, optimized lipid nanoparticle delivery, modular vaccine platform designs, rapid adaptation to pathogen targets, and advanced adjuvant systems.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33215&type=smp

Which Growth Factors Are Strengthening The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Landscape?

The rising need for personalized medicine is anticipated to fuel the expansion of the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market moving ahead. This medical strategy involves customizing disease prevention and treatment approaches according to an individual’s genetic makeup, molecular traits, and unique health circumstances. The surge in personalized medicine demand stems from the increasing occurrence of complex and persistent illnesses, which necessitate precise and patient-focused therapeutic interventions to enhance treatment effectiveness and safety results. Messenger ribonucleic acid (mRNA) and next-generation vaccine platforms facilitate personalized medicine by allowing for swift, adaptable, and highly targeted vaccine and treatment designs, which can be adapted to specific genetic and disease profiles, thereby supporting precision healthcare. For example, in February 2024, data from the Personalized Medicine Coalition, a US-based hospital and healthcare body, showed that in 2023, the FDA sanctioned 16 novel personalized therapies for rare disease patients, an increase from six in 2022. Consequently, the escalating demand for personalized medicine is propelling the expansion of the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market.

What Segment Types Are Included In The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Analysis?

The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market covered in this report is segmented –

1) By Vaccine Type: Messenger Ribonucleic Acid Vaccines; Deoxyribonucleic Acid (DNA) Vaccines; Viral Vector Vaccines; Protein Subunit Vaccines; Peptide Vaccines; Other Vaccine Types

2) By Technology or Platform: Lipid Nanoparticle (LNP) Delivery; Self-Amplifying Messenger Ribonucleic Acid; Circular Messenger Ribonucleic Acid; Replicon or Non-replicating Platforms; Viral Vector Technologies

3) By Disease Indication: Infectious Diseases; Oncology; Rare Diseases; Other Disease Indications

4) By End User: Pharmaceutical and Biotechnology Companies; Contract Research Organizations (CROs); Academic and Research Institutes; Hospitals and Clinics

Subsegments:

1) By Messenger Ribonucleic Acid Vaccines: Conventional Messenger Ribonucleic Acid Vaccines; Self Amplifying Messenger Ribonucleic Acid Vaccines; Modified Messenger Ribonucleic Acid Vaccines; Circular Messenger Ribonucleic Acid Vaccines

2) By Deoxyribonucleic Acid Vaccines: Plasmid Deoxyribonucleic Acid Vaccines; Viral Assisted Deoxyribonucleic Acid Vaccines; Synthetic Deoxyribonucleic Acid Vaccines; Gene Based Deoxyribonucleic Acid Vaccines

3) By Viral Vector Vaccines: Adenovirus Based Viral Vector Vaccines; Lentivirus Based Viral Vector Vaccines; Poxvirus Based Viral Vector Vaccines; Measles Virus Based Viral Vector Vaccines

4) By Protein Subunit Vaccines: Recombinant Protein Vaccines; Virus Like Particle Vaccines; Toxoid Based Protein Vaccines; Polysaccharide Conjugate Vaccines

5) By Peptide Vaccines: Synthetic Peptide Vaccines; Personalized Peptide Vaccines; Multi Epitope Peptide Vaccines; Long Peptide Vaccines

6) By Other Vaccine Types: Protein Subunit Vaccines, Virus-Like Particle Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vector Vaccines

Which Trends Are Contributing To Changes In The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market?

Leading enterprises within the mRNA and next-generation vaccine platforms market are concentrating on creating advanced mRNA-based COVID-19 vaccines, with the goal of strengthening immune persistence, expanding protection against variants, and elevating overall vaccine efficacy. These advanced mRNA vaccines utilize enhanced mRNA engineering and delivery methods, offering more extensive and lasting protection against current and developing SARS-CoV-2 variants. They also boost safety, stability, and ease of storage, alongside enabling swift adjustments to evolving viruses. An illustration of this is Moderna Inc., a US-based biotechnology company, launching mNEXSPIKE in June 2025. This next-generation COVID-19 vaccine is engineered to bolster defenses against both prevalent and newly appearing SARS-CoV-2 variants, featuring an updated spike protein antigen that more accurately aligns with recent variants. Its objective is to provide superior immune durability and efficacy, thereby assisting current COVID-19 prevention initiatives and future booster approaches.

Who Are The Businesses Driving Activity In The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market?

Major companies operating in the messenger ribonucleic acid (mrna) and next-generation vaccine platforms market are Pfizer Inc., Sanofi S.A., AstraZeneca PLC, Thermo Fisher Scientific Inc., GSK plc, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Moderna Inc., BioNTech SE, Novavax Inc., Walvax Biotechnology Co Ltd, Arcturus Therapeutics Inc, Gennova Biopharmaceuticals Ltd, Vaxxas Pty Ltd, Vaxart Inc, Ethris GmbH, The Biologicals and Vaccines Institute of Southern Africa Proprietary Limited, eTheRNA Immunotherapies NV, Stemirna Therapeutics Co Ltd, Primrose Bio Inc, Acuitas Therapeutics Inc, and Incepta Vaccine Ltd.

Access The Complete Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Report:

https://www.thebusinessresearchcompany.com/report/messenger-ribonucleic-acid-mrna-and-next-generation-vaccine-platforms-market-report

Which Region Is The Dominant Market In The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market?

North America was the largest region in the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the messenger ribonucleic acid (mrna) and next-generation vaccine platforms market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Report for Deeper Competitive Insights

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, What Market Size Is The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Expected To Reach Based On Its 2026 Value?

The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market size has expanded significantly in recent years. Projections indicate it will advance from $39.69 billion in 2025 to $45.88 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.6%. This historical growth can be attributed to various factors, including covid 19 vaccine breakthroughs, prior viral vector research, global pandemic preparedness programs, advances in genomic sequencing, and early nucleic acid vaccine trials.

The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market is anticipated to experience significant expansion in the upcoming years. It is projected to achieve a size of $82.61 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 15.8%. This growth during the forecast period can be attributed to factors such as the development of personalized cancer vaccines, the broadening of infectious disease pipelines, more rapid platform-based approvals, increased funding in biotechnology, and the wider application of therapeutic vaccines. Prominent trends expected in the forecast period include self-amplifying mrna platforms, optimized lipid nanoparticle delivery, modular vaccine platform designs, swift adaptation to pathogen targets, and innovative next-generation adjuvant systems.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33215&type=smp

What Key Drivers Are Fueling The Growth Of The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market?

Future expansion of the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market is anticipated due to the rising need for personalized medicine. Personalized medicine involves a healthcare strategy that customizes disease prevention and treatment plans according to an individual’s unique genetic makeup, molecular traits, and particular health circumstances. The escalating requirement for personalized medicine stems from the increasing occurrence of intricate and long-term illnesses, which necessitate precise and individualized therapeutic approaches to enhance both the effectiveness and safety of treatment. Messenger ribonucleic acid (mRNA) and next-generation vaccine platforms facilitate personalized medicine by allowing for quick, adaptable, and highly precise designs for vaccines and therapies, which can be adapted to specific genetic and disease profiles of individuals, thereby aiding in the provision of precision healthcare. As an illustration, the Personalized Medicine Coalition, a US-based hospital and health care organization, reported in February 2024 that the FDA cleared 16 novel personalized treatments for patients with rare diseases in 2023, an increase from six in 2022. Consequently, the expanding need for personalized medicine is fueling the expansion of the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market.

What Are The Different Segment Types In The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Segment Breakdown?

The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market covered in this report is segmented –

1) By Vaccine Type: Messenger Ribonucleic Acid Vaccines; Deoxyribonucleic Acid (DNA) Vaccines; Viral Vector Vaccines; Protein Subunit Vaccines; Peptide Vaccines; Other Vaccine Types

2) By Technology or Platform: Lipid Nanoparticle (LNP) Delivery; Self-Amplifying Messenger Ribonucleic Acid; Circular Messenger Ribonucleic Acid; Replicon or Non-replicating Platforms; Viral Vector Technologies

3) By Disease Indication: Infectious Diseases; Oncology; Rare Diseases; Other Disease Indications

4) By End User: Pharmaceutical and Biotechnology Companies; Contract Research Organizations (CROs); Academic and Research Institutes; Hospitals and Clinics

Subsegments:

1) By Messenger Ribonucleic Acid Vaccines: Conventional Messenger Ribonucleic Acid Vaccines; Self Amplifying Messenger Ribonucleic Acid Vaccines; Modified Messenger Ribonucleic Acid Vaccines; Circular Messenger Ribonucleic Acid Vaccines

2) By Deoxyribonucleic Acid Vaccines: Plasmid Deoxyribonucleic Acid Vaccines; Viral Assisted Deoxyribonucleic Acid Vaccines; Synthetic Deoxyribonucleic Acid Vaccines; Gene Based Deoxyribonucleic Acid Vaccines

3) By Viral Vector Vaccines: Adenovirus Based Viral Vector Vaccines; Lentivirus Based Viral Vector Vaccines; Poxvirus Based Viral Vector Vaccines; Measles Virus Based Viral Vector Vaccines

4) By Protein Subunit Vaccines: Recombinant Protein Vaccines; Virus Like Particle Vaccines; Toxoid Based Protein Vaccines; Polysaccharide Conjugate Vaccines

5) By Peptide Vaccines: Synthetic Peptide Vaccines; Personalized Peptide Vaccines; Multi Epitope Peptide Vaccines; Long Peptide Vaccines

6) By Other Vaccine Types: Protein Subunit Vaccines, Virus-Like Particle Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vector Vaccines

What Trends Are Influencing The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market?

Leading companies operating in the mRNA and next-generation vaccine platforms market are concentrating their efforts on the creation of advanced mRNA-based COVID-19 vaccines. This focus aims to boost immune durability, expand variant coverage, and elevate overall vaccine efficacy. These innovative mRNA-based COVID-19 vaccines harness enhanced mRNA engineering and sophisticated delivery technologies, providing more extensive and lasting protection against both current and emerging SARS-CoV-2 variants. Furthermore, they offer improved safety, greater stability, and enhanced storage convenience, alongside the capability for swift adaptation to viral evolution. As an illustration, in June 2025, Moderna Inc., a US-based biotechnology company, launched mNEXSPIKE, its next-generation COVID-19 vaccine. This vaccine is engineered to enhance protection against both circulating and newly emerging SARS-CoV-2 variants. mNEXSPIKE features an updated spike protein antigen, which more closely aligns with recent variants, and is intended to deliver superior immune durability and effectiveness, thereby bolstering ongoing COVID-19 prevention initiatives and future booster strategies.

Who Are The Well-Known Companies In The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market?

Major companies operating in the messenger ribonucleic acid (mrna) and next-generation vaccine platforms market are Pfizer Inc., Sanofi S.A., AstraZeneca PLC, Thermo Fisher Scientific Inc., GSK plc, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Moderna Inc., BioNTech SE, Novavax Inc., Walvax Biotechnology Co Ltd, Arcturus Therapeutics Inc, Gennova Biopharmaceuticals Ltd, Vaxxas Pty Ltd, Vaxart Inc, Ethris GmbH, The Biologicals and Vaccines Institute of Southern Africa Proprietary Limited, eTheRNA Immunotherapies NV, Stemirna Therapeutics Co Ltd, Primrose Bio Inc, Acuitas Therapeutics Inc, and Incepta Vaccine Ltd.

Get The Full Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Report:

https://www.thebusinessresearchcompany.com/report/messenger-ribonucleic-acid-mrna-and-next-generation-vaccine-platforms-market-report

Which Region Dominates The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market By Market Share?

North America was the largest region in the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the messenger ribonucleic acid (mrna) and next-generation vaccine platforms market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/customise?id=33215&type=smp

Browse Through More Reports Similar to the Global Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market 2026, By The Business Research Company

Mrna Cancer Vaccines And Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/mrna-cancer-vaccines-and-therapeutics-global-market-report

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Projected To Become By 2030 Based On Its 2026 Valuation?

The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market size has experienced swift expansion recently. It will grow from $39.69 billion in 2025 to $45.88 billion in 2026 at a compound annual growth rate (CAGR) of 15.6%. Historically, this expansion is attributable to covid 19 vaccine breakthroughs, prior viral vector research, global pandemic preparedness programs, advances in genomic sequencing, and early nucleic acid vaccine trials.

The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market is projected to experience substantial expansion over the upcoming years. Its valuation is anticipated to reach $82.61 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 15.8%. This anticipated growth during the forecast period stems from factors such as the rise of personalized cancer vaccines, the expansion of infectious disease development pipelines, swifter platform-based approval processes, increased funding in biotechnology, and the more extensive application of therapeutic vaccines. Key developments expected during this period involve self-amplifying mRNA platforms, enhanced lipid nanoparticle delivery, the implementation of modular vaccine platform designs, swift adaptation to pathogen targets, and the development of next-generation adjuvant systems.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33215&type=smp

What Drivers Are Expected To Influence The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market During The Forecast Period?

The burgeoning need for personalized medicine is anticipated to fuel the expansion of the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market moving ahead. Personalized medicine represents a healthcare strategy where methods for preventing and treating diseases are customized according to an individual’s genetic makeup, molecular traits, and particular health circumstances. The escalating requirement for personalized medicine stems from the increasing occurrence of intricate and long-term illnesses, given that these conditions necessitate precise and individual-focused therapeutic approaches to enhance the effectiveness and safety of treatments. Messenger ribonucleic acid (mRNA) and next-generation vaccine platforms facilitate personalized medicine by allowing for the quick, adaptable, and highly specialized creation of vaccines and therapies, which can be adapted to specific genetic and disease profiles, thereby aiding in the provision of precision healthcare. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based hospital and health care organization, reported that in 2023, the FDA sanctioned 16 new personalized treatments for rare disease patients, an increase from six in 2022. Consequently, the growing need for personalized medicine is propelling the expansion of the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market.

What Segment Groups Are Identified Within The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market?

The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market covered in this report is segmented –

1) By Vaccine Type: Messenger Ribonucleic Acid Vaccines; Deoxyribonucleic Acid (DNA) Vaccines; Viral Vector Vaccines; Protein Subunit Vaccines; Peptide Vaccines; Other Vaccine Types

2) By Technology or Platform: Lipid Nanoparticle (LNP) Delivery; Self-Amplifying Messenger Ribonucleic Acid; Circular Messenger Ribonucleic Acid; Replicon or Non-replicating Platforms; Viral Vector Technologies

3) By Disease Indication: Infectious Diseases; Oncology; Rare Diseases; Other Disease Indications

4) By End User: Pharmaceutical and Biotechnology Companies; Contract Research Organizations (CROs); Academic and Research Institutes; Hospitals and Clinics

Subsegments:

1) By Messenger Ribonucleic Acid Vaccines: Conventional Messenger Ribonucleic Acid Vaccines; Self Amplifying Messenger Ribonucleic Acid Vaccines; Modified Messenger Ribonucleic Acid Vaccines; Circular Messenger Ribonucleic Acid Vaccines

2) By Deoxyribonucleic Acid Vaccines: Plasmid Deoxyribonucleic Acid Vaccines; Viral Assisted Deoxyribonucleic Acid Vaccines; Synthetic Deoxyribonucleic Acid Vaccines; Gene Based Deoxyribonucleic Acid Vaccines

3) By Viral Vector Vaccines: Adenovirus Based Viral Vector Vaccines; Lentivirus Based Viral Vector Vaccines; Poxvirus Based Viral Vector Vaccines; Measles Virus Based Viral Vector Vaccines

4) By Protein Subunit Vaccines: Recombinant Protein Vaccines; Virus Like Particle Vaccines; Toxoid Based Protein Vaccines; Polysaccharide Conjugate Vaccines

5) By Peptide Vaccines: Synthetic Peptide Vaccines; Personalized Peptide Vaccines; Multi Epitope Peptide Vaccines; Long Peptide Vaccines

6) By Other Vaccine Types: Protein Subunit Vaccines, Virus-Like Particle Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vector Vaccines

What Trends Are Advancing Progress In The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market?

Leading companies within the mRNA and next-generation vaccine platforms market are concentrating on developing advanced mRNA-based COVID-19 vaccines. This focus aims to boost immune endurance, widen coverage against variants, and elevate overall vaccine efficacy. These next-generation mRNA-based COVID-19 vaccines utilize enhanced mRNA engineering and delivery methods, offering more extensive and lasting defense against current and emerging SARS-CoV-2 variants, while also improving safety, stability, and ease of storage, alongside facilitating rapid adaptation to viral evolution. As an illustration, in June 2025, Moderna Inc., a US-based biotechnology company, unveiled mNEXSPIKE, its next-generation COVID-19 vaccine, engineered to bolster defense against prevalent and new SARS-CoV-2 variants. This vaccine features an updated spike protein antigen that better corresponds to recent variants, seeking to provide superior immune durability and effectiveness, thereby aiding continuous COVID-19 prevention initiatives and subsequent booster approaches.

Who Are The Prominent Organizations Shaping The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market?

Major companies operating in the messenger ribonucleic acid (mrna) and next-generation vaccine platforms market are Pfizer Inc., Sanofi S.A., AstraZeneca PLC, Thermo Fisher Scientific Inc., GSK plc, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Moderna Inc., BioNTech SE, Novavax Inc., Walvax Biotechnology Co Ltd, Arcturus Therapeutics Inc, Gennova Biopharmaceuticals Ltd, Vaxxas Pty Ltd, Vaxart Inc, Ethris GmbH, The Biologicals and Vaccines Institute of Southern Africa Proprietary Limited, eTheRNA Immunotherapies NV, Stemirna Therapeutics Co Ltd, Primrose Bio Inc, Acuitas Therapeutics Inc, and Incepta Vaccine Ltd.

Read the full messenger ribonucleic acid (mrna) and next-generation vaccine platforms market report here:

https://www.thebusinessresearchcompany.com/report/messenger-ribonucleic-acid-mrna-and-next-generation-vaccine-platforms-market-report

Which Region Is Anticipated To See The Fastest Growth In The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market?

North America was the largest region in the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the messenger ribonucleic acid (mrna) and next-generation vaccine platforms market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=33215&type=smp

Browse Through More Reports Similar to the Global Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market 2026, By The Business Research Company

Mrna Cancer Vaccines And Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/mrna-cancer-vaccines-and-therapeutics-global-market-report

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the messenger ribonucleic acid (mrna) and next-generation vaccine platforms market from 2026–2035 with trusted insights from The Business Research Company

What growth pattern is forecast for the Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market size between 2026 and 2035?

The market size for messenger ribonucleic acid (mrna) and next-generation vaccine platforms has experienced swift expansion recently. This market is projected to expand from $39.69 billion in 2025 to $45.88 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 15.6%. Key factors contributing to its historical growth include covid 19 vaccine breakthroughs, prior viral vector research, global pandemic preparedness programs, advances in genomic sequencing, and early nucleic acid vaccine trials.

The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market is anticipated to undergo significant expansion in the coming years. Its valuation is projected to reach $82.61 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 15.8%. This growth during the forecast period can be attributed to factors such as the rise of personalized cancer vaccines, the broadening of infectious disease pipelines, swifter platform-based approvals, increased funding in biotechnology, and the more extensive application of therapeutic vaccines. Prominent trends for the forecast period include self-amplifying mRNA platforms, advancements in lipid nanoparticle delivery, the adoption of modular vaccine platform designs, quick adaptation to pathogen targets, and the emergence of next-generation adjuvant systems.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33215&type=smp

Which Drivers Are Impacting Market Performance In The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market?

The escalating need for personalized medicine is anticipated to propel the growth of the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market going forward. Personalized medicine, a medical approach, involves customizing disease prevention and treatment strategies based on an individual’s genetic profile, molecular characteristics, and specific health conditions. The heightened demand for personalized medicine stems from the rising prevalence of complex and chronic diseases, as these conditions necessitate targeted and patient-specific therapeutic solutions to enhance treatment efficacy and safety outcomes. Messenger ribonucleic acid (mRNA) and next-generation vaccine platforms aid personalized medicine by enabling rapid, flexible, and highly specific vaccine and therapeutic designs that can be tailored to individual genetic and disease profiles, thereby supporting precision-based healthcare delivery. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and health care organization, 16 new personalized treatments for rare disease patients received FDA approval in 2023, an increase from six in 2022. Therefore, the escalating demand for personalized medicine is driving the expansion of the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market.

What Segment Types Are Examined In The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market?

The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market covered in this report is segmented –

1) By Vaccine Type: Messenger Ribonucleic Acid Vaccines; Deoxyribonucleic Acid (DNA) Vaccines; Viral Vector Vaccines; Protein Subunit Vaccines; Peptide Vaccines; Other Vaccine Types

2) By Technology or Platform: Lipid Nanoparticle (LNP) Delivery; Self-Amplifying Messenger Ribonucleic Acid; Circular Messenger Ribonucleic Acid; Replicon or Non-replicating Platforms; Viral Vector Technologies

3) By Disease Indication: Infectious Diseases; Oncology; Rare Diseases; Other Disease Indications

4) By End User: Pharmaceutical and Biotechnology Companies; Contract Research Organizations (CROs); Academic and Research Institutes; Hospitals and Clinics

Subsegments:

1) By Messenger Ribonucleic Acid Vaccines: Conventional Messenger Ribonucleic Acid Vaccines; Self Amplifying Messenger Ribonucleic Acid Vaccines; Modified Messenger Ribonucleic Acid Vaccines; Circular Messenger Ribonucleic Acid Vaccines

2) By Deoxyribonucleic Acid Vaccines: Plasmid Deoxyribonucleic Acid Vaccines; Viral Assisted Deoxyribonucleic Acid Vaccines; Synthetic Deoxyribonucleic Acid Vaccines; Gene Based Deoxyribonucleic Acid Vaccines

3) By Viral Vector Vaccines: Adenovirus Based Viral Vector Vaccines; Lentivirus Based Viral Vector Vaccines; Poxvirus Based Viral Vector Vaccines; Measles Virus Based Viral Vector Vaccines

4) By Protein Subunit Vaccines: Recombinant Protein Vaccines; Virus Like Particle Vaccines; Toxoid Based Protein Vaccines; Polysaccharide Conjugate Vaccines

5) By Peptide Vaccines: Synthetic Peptide Vaccines; Personalized Peptide Vaccines; Multi Epitope Peptide Vaccines; Long Peptide Vaccines

6) By Other Vaccine Types: Protein Subunit Vaccines, Virus-Like Particle Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vector Vaccines

Which Trends Are Guiding The Evolution Of The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market?

Major companies in the mRNA and next-generation vaccine platforms market are prioritizing the development of advanced mRNA-based COVID-19 vaccines to enhance immune endurance, broaden variant coverage, and improve overall vaccine performance. These next-generation mRNA COVID-19 vaccines leverage refined mRNA engineering and delivery technologies to provide more extensive and lasting protection against existing and emerging SARS-CoV-2 variants, while also boosting safety, stability, and storage convenience, and allowing for rapid adaptation to viral evolution. For instance, in June 2025, Moderna Inc., a US-based biotechnology company, launched mNEXSPIKE, its next-generation COVID-19 vaccine designed to strengthen protection against circulating and emerging SARS-CoV-2 variants. This vaccine features an updated spike protein antigen that more accurately matches recent variants, aiming to deliver enhanced immune durability and effectiveness to support ongoing COVID-19 prevention efforts and future booster strategies.

Who Are The Major Companies Operating In The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market?

Major companies operating in the messenger ribonucleic acid (mrna) and next-generation vaccine platforms market are Pfizer Inc., Sanofi S.A., AstraZeneca PLC, Thermo Fisher Scientific Inc., GSK plc, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Moderna Inc., BioNTech SE, Novavax Inc., Walvax Biotechnology Co Ltd, Arcturus Therapeutics Inc, Gennova Biopharmaceuticals Ltd, Vaxxas Pty Ltd, Vaxart Inc, Ethris GmbH, The Biologicals and Vaccines Institute of Southern Africa Proprietary Limited, eTheRNA Immunotherapies NV, Stemirna Therapeutics Co Ltd, Primrose Bio Inc, Acuitas Therapeutics Inc, and Incepta Vaccine Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/messenger-ribonucleic-acid-mrna-and-next-generation-vaccine-platforms-market-report

Which Region Is Anticipated To See The Fastest Growth In The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market?

North America was the largest region in the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the messenger ribonucleic acid (mrna) and next-generation vaccine platforms market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=33215&type=smp

Browse Through More Reports Similar to the Global Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market 2026, By The Business Research Company

Mrna Cancer Vaccines And Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/mrna-cancer-vaccines-and-therapeutics-global-market-report

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model